Background and Aims
The molecular, endoscopic, and histological features of IBD-associated CRC differ from sporadic CRC. The objective of this study was to describe the prevalence, clinical features, and prognosis of IBD-associated CRC compared to patients with sporadic CRC in a US statewide population-based cohort.
All newly diagnosed cases of CRC between 1996 and 2011 were obtained from Utah Cancer Registry. IBD was identified using a previously validated algorithm, from statewide databases of Intermountain Healthcare, University of Utah Health Sciences, and the Utah Population Database. Logistic regression was performed to identify risk factors associated with IBD-associated cancer and Cox regression for differences in survival.
Among 12,578 patients diagnosed with CRC, 101 (0.8%) had a prior history of IBD (61 ulcerative colitis and 40 Crohn’s disease). The mean age at CRC diagnosis was greater for patients without IBD than those with IBD (67.1 vs 52.8 years, P < 0.001). Individuals with IBD-associated CRC were more likely to be men (odds ratio [OR] 1.90, 95% CI 1.23–2.92), aged less than 65 years (OR 6.77, 95% CI 4.06–11.27), and have CRC located in the proximal colon (OR 2.79, 95% CI 1.85–4.20) than those with sporadic CRC. Nearly 20% of the IBD-associated CRCs had evidence of primary sclerosing cholangitis. After adjustment for age, gender, and stage at diagnosis, the excess hazard of death after CRC diagnosis was 1.7 times higher in IBD than in non-IBD patients (95% CI 1.27–2.33).
The features of patients with CRC and IBD differ significantly from those without IBD and may be associated with increased mortality.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91:854–862.
Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18:1–5.
Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–535.
Jess T, Gamborg M, Matzen P, et al. Increased risk of intestinal cancer in Crohn’s disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005;100:2724–2729.
Eaden JA, Mayberry JF. Colorectal cancer complicating ulcerative colitis: a review. Am J Gastroenterol. 2000;95:2710–2719.
Askling J, Dickman PW, Karlen P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology. 2001;120:1356–1362.
Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut. 1997;41:522–525.
Jayaram H, Satsangi J, Chapman RW. Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: fact or fiction? Gut. 2001;48:430–434.
Yashiro M. Molecular alterations of colorectal cancer with inflammatory bowel disease. Dig Dis Sci. 2015;60:2251–2263.
Delaunoit T, Limburg PJ, Goldberg RM, et al. Colorectal cancer prognosis among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:335–342.
Gearhart SL, Nathan H, Pawlik TM, et al. Outcomes from IBD-associated and non-IBD-associated colorectal cancer: a surveillance epidemiology and end results medicare study. Dis Colon Rectum. 2012;55:270–277.
Ali RA, Dooley C, Comber H, et al. Clinical features, treatment, and survival of patients with colorectal cancer with or without inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:e1–e2.
Peyrin-Biroulet L, Lepage C, Jooste V, et al. Colorectal cancer in inflammatory bowel diseases: a population-based study (1976–2008). Inflamm Bowel Dis. 2012;18:2247–2251.
Ording AG, Horvath-Puho E, Erichsen R, et al. Five-year mortality in colorectal cancer patients with ulcerative colitis or Crohn’s disease: a nationwide population-based cohort study. Inflamm Bowel Dis. 2013;19:800–805.
Brackmann S, Aamodt G, Andersen SN, et al. Widespread but not localized neoplasia in inflammatory bowel disease worsens the prognosis of colorectal cancer. Inflamm Bowel Dis. 2010;16:474–481.
Watanabe T, Konishi T, Kishimoto J, et al. Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. Inflamm Bowel Dis. 2011;17:802–808.
DuVall SL, Kerber RA, Thomas A. Extending the Fellegi-Sunter probabilistic record linkage method for approximate field comparators. J Biomed Inform. 2010;43:24–30.
Duvall SL, Fraser AM, Rowe K, et al. Evaluation of record linkage between a large healthcare provider and the Utah Population Database. J Am Med Inform Assoc. 2012;19:e54–e59.
Bernstein CN, Wajda A, Svenson LW, et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol. 2006;101:1559–1568.
Benchimol EI, Guttmann A, Mack DR, et al. Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada. J Clin Epidemiol. 2014;67:887–896.
Soderlund S, Granath F, Brostrom O, et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology. 2010;138:1697–1703.
Jorde LB. Inbreeding in the Utah Mormons: an evaluation of estimates based on pedigrees, isonymy, and migration matrices. Ann Hum Genet. 1989;53:339–355.
West DW, Lyon JL, Gardner JW. Cancer risk factors: an analysis of Utah Mormons and non-Mormons. J Natl Cancer Inst. 1980;65:1083–1095.
The study was funded by the Crohn’s and Colitis Foundation of America, National Cancer Institute, American College of Gastroenterology, and the Huntsman Cancer Foundation. The funding sources did not play a role in the design, conduct, or reporting of the study or in the decision to submit the manuscript for publication.
Support for this project was provided by the Crohn’s and Colitis Foundation of America Senior Research Award (NJS), NCI Grants P01-CA073992 (RWB), R01-CA040641 (RWB), and a Junior Faculty Career Development Award from the American College of Gastroenterology (NJS). Partial support for the Utah Population Database and this project was provided by the Huntsman Cancer Institute Cancer Center Support Grant P30CA042014 from the National Cancer institute and the Huntsman Cancer Foundation. Support for the Utah Cancer Registry is provided by Contract #HHSN 261201000026C from the National Cancer Institute with additional support from the Utah Department of Health and the University of Utah.
Drs. Samadder and Curtin had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analyses. NJS, RWB, KS, JV, SG, CNB, and HS contributed to study concept and design; KS, KC, KR, JW, YW, RWB, and NJS acquired, analyzed, and interpreted the data; NJS drafted the manuscript; KC, KS, RWB, CU, CB, SG, HH, MB, and KR critically revised the manuscript for important intellectual content; LP, KB, and KS contributed to statistical analysis; and NJS and RWB obtained funding.
Conflict of interest
NJS is a consultant for Cook Medical. CNB has consulted to Abbvie Canada, Ferring Canada, Janssen Canada, Pfizer Canada, Shire Canada, Takeda Canada, Mylan Pharmaceuticals, and Bristol Myers Squibb. HS has consulted to Pendopharm and received a Research Grant from Merck Canada. No other authors have a conflict of interest to disclose.
About this article
Cite this article
Jewel Samadder, N., Valentine, J.F., Guthery, S. et al. Colorectal Cancer in Inflammatory Bowel Diseases: A Population-Based Study in Utah. Dig Dis Sci 62, 2126–2132 (2017). https://doi.org/10.1007/s10620-016-4435-4
- Inflammatory bowel disease
- Crohn’s disease
- Ulcerative colitis
- Colorectal cancer